Bromelain topical - MediWound
Alternative Names: anacaulase-bcdb; Debrase; Debrase Gel Dressing; KMW-1; NexoBrid; NexoBridNLatest Information Update: 03 Jun 2024
At a glance
- Originator MediWound
- Developer Kaken Pharmaceutical; MediWound; Teva Pharmaceutical Industries; Tuteur
- Class Anti-inflammatories; Cysteine endopeptidases; Skin disorder therapies
- Mechanism of Action Peptide hydrolase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Burns
- No development reported Wounds
Most Recent Events
- 29 May 2024 MediWound completes enrolment in the Expanded Access Treatment Protocol (NEXT) trial for Burns in USA, prior to May 2024 (NCT04040660)
- 21 Mar 2024 MediWound anticipates approval of sBLA from the US FDA for Burns (In adolescents, In children, In infants, In neonates), in the second half of 2024
- 10 Jan 2024 Preregistration for Burns (In adolescents, In children, In infants, In neonates) in USA (Topical)